Total Payments
$13,780
2024 Payments
$1,907
Companies
65
Transactions
762
Medicare Patients
4,033
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$12,530 (90.9%)
Education$856.55 (6.2%)
Consulting$393.75 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,530 | 745 | 90.9% |
| Education | $856.55 | 16 | 6.2% |
| Consulting Fee | $393.75 | 1 | 2.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,770 | 95 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,576 | 80 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,486 | 100 | $0 (2024) |
| PFIZER INC. | $922.91 | 59 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $708.87 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $676.93 | 43 | $0 (2024) |
| Amgen Inc. | $569.54 | 30 | $0 (2023) |
| Astellas Pharma US Inc | $529.43 | 24 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $497.95 | 27 | $0 (2024) |
| Incyte Corporation | $410.07 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,907 | 78 | Novartis Pharmaceuticals Corporation ($459.58) |
| 2023 | $1,901 | 95 | Merck Sharp & Dohme LLC ($195.29) |
| 2022 | $2,020 | 109 | Daiichi Sankyo Inc. ($498.17) |
| 2021 | $1,952 | 102 | Daiichi Sankyo Inc. ($439.55) |
| 2020 | $1,258 | 86 | Merck Sharp & Dohme Corporation ($251.76) |
| 2019 | $1,395 | 98 | Novartis Pharmaceuticals Corporation ($291.18) |
| 2018 | $1,609 | 114 | Novartis Pharmaceuticals Corporation ($256.45) |
| 2017 | $1,738 | 80 | Daiichi Sankyo Inc. ($267.08) |
All Payment Transactions
762 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq, Tecentriq Hybreza | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: BioOncology | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $19.68 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Genetically Defined Disease | ||||||
| 11/19/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Genetically Defined Disease | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.66 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: HEMATOLOGY | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.88 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Hematology | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $393.75 | General |
| 10/16/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: Rare Disease | ||||||
| 10/15/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Genetically Defined Disease | ||||||
| 10/09/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.00 | General |
| 10/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $27.28 | General |
| 09/20/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: HEMATOLOGY | ||||||
| 09/19/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Genetically Defined Disease | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.03 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.99 | General |
| Category: Hematology/Oncology | ||||||
| 09/12/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), Fabhalta | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.52 | General |
| Category: Hematology/Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 712 | 17,249 | $1.0M | $280,228 |
| 2022 | 11 | 1,064 | 15,800 | $670,660 | $260,241 |
| 2021 | 14 | 1,246 | 16,013 | $921,723 | $378,810 |
| 2020 | 13 | 1,011 | 17,209 | $738,968 | $303,635 |
Total Patients
4,033
Total Services
66,271
Medicare Billing
$1.2M
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 253 | 1,013 | $242,319 | $107,698 | 44.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 33 | 15,200 | $591,110 | $89,485 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 171 | 295 | $88,711 | $45,101 | 50.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 148 | 352 | $54,236 | $25,667 | 47.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 59 | 59 | $21,020 | $7,491 | 35.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 37 | 317 | $22,819 | $3,906 | 17.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 13 | $2,034 | $879.32 | 43.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 204 | 802 | $200,500 | $86,974 | 43.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 27 | 12,780 | $255,600 | $82,319 | 32.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 132 | 222 | $66,600 | $32,405 | 48.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 144 | 289 | $46,818 | $21,969 | 46.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 70 | 70 | $25,900 | $9,527 | 36.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 345 | 1,094 | $32,820 | $8,317 | 25.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 16 | 50 | $8,000 | $7,984 | 99.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 31 | 320 | $15,952 | $4,033 | 25.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $9,890 | $3,929 | 39.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 34 | $5,100 | $2,075 | 40.7% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 55 | 116 | $3,480 | $709.70 | 20.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 213 | 782 | $195,500 | $88,894 | 45.5% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2021 | 33 | 12,450 | $249,000 | $83,954 | 33.7% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2021 | 13 | 23 | $172,500 | $51,276 | 29.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 163 | 311 | $93,300 | $49,050 | 52.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 55 | 270 | $43,200 | $43,237 | 100.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 141 | 306 | $49,572 | $23,313 | 47.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 379 | 1,305 | $39,121 | $10,126 | 25.9% |
About Dr. Mark Pascal, MD
Dr. Mark Pascal, MD is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700847373.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Pascal, MD has received a total of $13,780 in payments from pharmaceutical and medical device companies, with $1,907 received in 2024. These payments were reported across 762 transactions from 65 companies. The most common payment nature is "Food and Beverage" ($12,530).
As a Medicare-enrolled provider, Pascal has provided services to 4,033 Medicare beneficiaries, totaling 66,271 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 03/31/2006
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1700847373
Products in Payments
- KEYTRUDA (Biological) $1,266
- INJECTAFER (Drug) $814.20
- KISQALI (Drug) $479.97
- ULTOMIRIS (Biological) $470.34
- OPDIVO (Biological) $457.96
- Enhertu (Drug) $390.64
- ELIQUIS (Drug) $347.20
- ENHERTU (Drug) $317.00
- PROMACTA (Drug) $315.05
- Lenvima (Drug) $240.06
- LIBTAYO (Biological) $228.62
- DARZALEX (Biological) $214.24
- IBRANCE (Drug) $200.83
- JAKAFI (Drug) $196.89
- Imbruvica (Drug) $196.19
- CHANTIX (Drug) $193.67
- XTANDI (Drug) $192.93
- LUMAKRAS (Drug) $192.23
- PADCEV (Drug) $184.71
- IMFINZI (Biological) $182.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. James Mccloskey, M.d, M.D
Hematology — Payments: $2.8M
Hematology $2.8M
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. David Vesole, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
Dr. Lori Leslie, M.d, M.D
Hematology — Payments: $669,511
Hematology $669,511
Dr. Robert Alter, Md, MD
Hematology — Payments: $539,884
Hematology $539,884